🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For all the cell therapy lovers, don't miss this conference in Paris! Gustave Roussy @ Société Française d'Immuno-Thérapie du Cancer

If you want to know everything on #IBD patient empowerment in research and how to design a patient centered study with state-of-the-art monitoring, register to the #EpiCom workshop at next #ECCO congress! ecco-ibd.eu/discover-the-p… Sophie Restellini Iago Rodriguez-Lago Peter Bossuyt EFCCA

🆕Finally, it's out! 🚨⏩⏩Published in Nature Communications our study on mucosal host-microbe interactions in association with clinical phenotypes in inflammatory bowel disease: nature.com/articles/s4146… WeersmaLab Shixian A 🧵below:

C. Reenaers presenting histologic data of the STORI trial 👏 👏

Honored to have received an ECCO grant to support our work on mucosal immunity in IBD! #ECCO2024 Y-ECCO GETAID

Look at our review on Neutrophils, IBD and Microbiota, with Camille Danne !

IMPROVING ADOPTIVE CELL THERAPY Deadline for abstract submission at : April 2, 2024 Please submit your abstract to the following address: [email protected]

Very pleased to see this paper on the role of the gut microbiota in IgA nephropathy published in Science Translational Medicine! It was a pleasure to contribute to this study coordinated by R Monteiro and James Gleeson! science.org/doi/10.1126/sc… @inserm Sorbonne Université Université Paris Cité #Thread 1/11

We started this a while ago with a great team effort of the Mehandru Lab @MountSinai and many collaborators. Proud to share this story giving new insights into vedolizumab MOA. Read Pablo Canales-Herrerias ‘s great thread 👇

We are hiring a motivated #postdoc with experience in #bioinformatics and #metagenomics to work on #microbiome #ERC-funded project in a stimulating environment. Join us in #Paris ! Inserm @MedecineSU crsaparis please RT See details here 🔽🔽🔽🔽 sites.google.com/site/harrysoko…

Long-term outcome of risankizumab in Crohn’s disease: a real-world GETAID study ▶️174 patients exposed >=3 biologics ▶️ steroid-free clinical remission : 47% w26, 46% w52 ▶️One year discontinuation : 26% (LOR, 42%; Ir failure, 37%; intolerance, 13%) cghjournal.org/article/S1542-…

This is an important observation from a well conducted study from WeersmaLab 👏👏 We need to think whether microbiome research in some aspects of # IBD is at risk of becoming a fishing 🎣 expedition 🤔

Very grateful to our star speakers for great science during our Cell Therapy conf Gustave Roussy @realFlorentGinhoux Julie Helft Justin Eyquem Belkaid Lab @realFlorentGinhoux Katy Rezvani, M.D., Ph.D Marson Lab Majzner_Lab Julie Helft Alena Gros @amigorena Roychoudhuri Lab Luca Gattinoni Claire Roddie

Message important de la #SNFGE sur l’inutilité des tests microbiotes et des test d’allergie alimentaire par mesure des IgG youtu.be/hQEUg02pcq4?si…

Dr Mark Silverberg NickPowellLab IBD Genetics Consortium NIDDK Matthieu Allez Not sure about FMT, but, with Matthieu Allez and the #REMIND group, we will soon start a study evaluating the effects of Faecalibacterium prausnitzii in postoperative settings

Le Séminaire GETAID-REMIND aura lieu le jeudi 5 décembre et le vendredi 6 décembre 2024 ! 🎉 Les inscriptions sont ouvertes 😃

Les inscriptions pour la Masterclass du GETAID sont lancées ! 🥳 Au programme : mises au point, échanges avec les experts, ateliers,... Le programme complet disponible ici : getaid.org/actualites/mas…

A true legend ⭐️

Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: the ERIC study CD patients from Saint-Antoine and Beaujon Hospital comparing Early vs Late resections onlinelibrary.wiley.com/doi/10.1111/ap… roypounder.apt Philippe Seksik Julien Kirchgesner Harry Sokol

Congrats! Huge achievement 👏 👏